impact, innovation, investment, Oxford, techtransfer, translation, TTO Oxford Science Enterprises raised a further £250 million ($300 million) in funding Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, announced … more ➔
Swedish Bioinvent issues shares worth SEK299m (USD28m) BioInvent has successfully carried out a directed share issue of approximately SEK 300 million (approximately USD 28.3 million). A number of international and Swedish investors participated, including … more ➔
Immunocore has a sip with USD140m private placementImmunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline. more ➔
biotech, consumer health, GSK, Haleon, IPO, listing, London, pharma, split, stock exchange GSK splits off consumer health as Haleon – first stock listing today GlaxoSmithKline (GSK), one of the UK’s large pharma player, has voted to spin-off its consumer healthcare business into a new company called Haleon. Shareholders gave the go-ahead for GSK … more ➔
Polpharma Biologics Announces EMA Acceptance for Proposed Biosimilar Natalizumab (Tysabri) European Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS). more ➔
Agomab extenses Series B with USD40m Bringing Total Amount to USD114m Agomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount … more ➔
Spatial Biology Company Navinci (Olink) closes EUR9m Series A Navinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round … more ➔
ADC, cancer, Chris Martin, Lausanne, orphan, Sobi, Swedish, Zynlonta Swedish SOBI awarded rights to market Zynlonta from ADC therapeuticsIn a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US. more ➔
bioeconomy, biosyntia, bonn, brandkamp, circular, denmark, ECBF, financing, fund ECBF joins Novo Seeds and Sofinnova Partners in EUR11.5m round in BiosyntiaThe European Circular Bioeconomy Fund (ECBF) expands its industrial biotechnology portfolio by joining the financing Series B of danish Biosyntia ApS. Biosyntia is a precision fermentation company focused … more ➔
Lonza invests CHF500m in Large-Scale Facility in Stein (CH) Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m. more ➔
